Paul J. Reider
Paul Joseph Reider (born June 7, 1951 in New York City ) is an American chemist .
Reider studied psychology (with chemistry as a minor) at Washington Square College in New York City with a bachelor's degree in 1972 and received his doctorate in organic chemistry from the University of Vermont in 1978 with Martin E. Kuehne . After he was a postdoctoral fellow of the National Institutes of Health at Colorado State University in 1980, he joined Merck in research in 1980 . In 1995 he became Vice President for Process Research. He was later Vice President and Head of Chemical Research at Amgen in Thousand Oakes, California, and most recently a pharmacy specialist and lecturer at Princeton University (2013).
Under his leadership, the COX-2 inhibitor etoricoxib and the HIV protease inhibitor indinavir (Crixivan) were developed - with total synthesis and its industrial implementation in the mid-1990s under extreme time pressure (it was one of the first two HIV protease inhibitors and was urgently expected) - and efavirenz from the NNRTI group , also against HIV .
In 2011 he received the NAS Award for Chemistry in Service to Society for contributions to the development of numerous drugs e.g. B. in asthma and HIV infection. In 2003 he received the ACS Earl B. Barnes Award for leadership role in chemical research management.
Web links
Individual evidence
- ↑ Date of birth according to American Men and Women of Science , Thomson Gale 2004.
| personal data | |
|---|---|
| SURNAME | Reider, Paul J. |
| ALTERNATIVE NAMES | Reider, Paul Joseph (full name) |
| BRIEF DESCRIPTION | American chemist |
| DATE OF BIRTH | June 7, 1951 |
| PLACE OF BIRTH | New York City |